Ivermectin just went from $25 to $1200 a dose.
So interesting that small, non-randomized trials showing marginal benefit (68%) for Remdesivir is presented as "great hope" by the MSM, but much larger studies for Hydroxychloroquine and Azithromycin that prove 91% effectiveness mean nothing and are just "dangerous."
— Mike Coudrey (@MichaelCoudrey) April 12, 2020